Literature DB >> 32380290

Ostial dimensional changes after pulmonary vein isolation: Pulsed field ablation vs radiofrequency ablation.

Kenji Kuroki1, William Whang1, Charles Eggert2, Jeff Lam1, Jonas Leavitt1, Iwanari Kawamura1, Ananya Reddy1, Blake Morrow2, Christopher Schneider2, Jan Petru3, Mohit Turagam1, Jacob S Koruth1, Marc A Miller1, Subbarao Choudry1, Betsy Ellsworth1, Srinivas R Dukkipati1, Petr Neuzil3, Vivek Y Reddy4.   

Abstract

BACKGROUND: Pulmonary vein (PV) stenosis is an important potential complication of PV isolation using thermal modalities such as radiofrequency ablation (RFA). Pulsed field ablation (PFA) is an alternative energy that causes nonthermal myocardial cell death.
OBJECTIVE: The purpose of this study was to compare the effect of PFA vs RFA on the incidence and severity of PV narrowing or stenosis.
METHODS: Data were analyzed from 4 paroxysmal atrial fibrillation ablation trials using either PFA or RFA; because of absent CT scans or poor computed tomography scan quality, 73 of 153 patients were excluded. Baseline and 3-month cardiac computed tomography scans were reconstructed into 3-dimensional images, and the long and short axes of the PV ostia were quantitatively and qualitatively assessed in a randomized blinded manner by 2 physicians.
RESULTS: A total of 299 PVs from 80 patients after either PFA (n = 37) or RFA (n = 43) were enrolled. PV ostial diameters decreased significantly less with PFA than with RFA (% change; long axis: 0.9% ± 8.5% vs -11.9% ± 16.3%; P < .001 and short axis: 3.4% ± 12.7% vs -12.9% ± 18.5%; P < .001). After a combined quantitative/qualitative analysis, mild (30%-49%), moderate (50%-69%), or severe (70%-100%) PV narrowing was observed, respectively, in 9.0% (15 of 166), 1.8% (3 of 166), and 1.2% (2 of 166) of PVs in the RFA cohort but in none of the PVs after PFA (P < .001). Overall, PV narrowing/stenosis was present in 0% and 0% vs 12.0% and 32.5% of PVs and patients who underwent PFA and RFA, respectively.
CONCLUSION: This study indicates that unlike after RFA, the incidence and severity of PV narrowing/stenosis after PV isolation is virtually eliminated with PFA.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Catheter ablation; Electroporation; Nonthermal ablation; Pulmonary vein stenosis; Pulsed field ablation

Year:  2020        PMID: 32380290     DOI: 10.1016/j.hrthm.2020.04.040

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  4 in total

Review 1.  [Catheter ablation : Developments and technique selection].

Authors:  L Yahsaly; J Siebermair; R Wakili
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2022-02-18

Review 2.  [Pulmonary vein isolation in atrial fibrillation using pulsed field ablation].

Authors:  F Lindemann; S Nedios; T Seewöster; G Hindricks
Journal:  Herz       Date:  2021-06-17       Impact factor: 1.443

3.  Letter from the Editor in Chief.

Authors:  Moussa Mansour
Journal:  J Innov Card Rhythm Manag       Date:  2021-04-15

4.  Multi-national survey on the methods, efficacy, and safety on the post-approval clinical use of pulsed field ablation (MANIFEST-PF).

Authors:  Emmanuel Ekanem; Vivek Y Reddy; Boris Schmidt; Tobias Reichlin; Kars Neven; Andreas Metzner; Jim Hansen; Yuri Blaauw; Philippe Maury; Thomas Arentz; Philipp Sommer; Ante Anic; Frederic Anselme; Serge Boveda; Tom Deneke; Stephan Willems; Pepijn van der Voort; Roland Tilz; Moritoshi Funasako; Daniel Scherr; Reza Wakili; Daniel Steven; Josef Kautzner; Johan Vijgen; Pierre Jais; Jan Petru; Julian Chun; Laurent Roten; Anna Füting; Andreas Rillig; Bart A Mulder; Arne Johannessen; Anne Rollin; Heiko Lehrmann; Christian Sohns; Zrinka Jurisic; Arnaud Savoure; Stephanes Combes; Karin Nentwich; Melanie Gunawardene; Alexandre Ouss; Bettina Kirstein; Martin Manninger; Jan Eric Bohnen; Arian Sultan; Petr Peichl; Pieter Koopman; Nicolas Derval; Mohit K Turagam; Petr Neuzil
Journal:  Europace       Date:  2022-09-01       Impact factor: 5.486

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.